Sign in
CompletedNo phase

Multicentric Clinical Study on Isatis TF Trifocal Intraocular Lens

Key facts

Who runs it
Cutting Edge SAS
Where
Czechia and Spain7 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Completed
People taking part
188 people enrolled
Started
31 May 2021
Ended
27 Jun 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Implantation of trifocal IOL, Isatis TF (device under investigation)
  • Implantation of monofocal IOL, Isatis (control device)
Record updated
12 February 2025

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Clinically documented age-related cataract in both eyes with no comorbidity
  • Calculated IOL power is within the range of the investigational IOLs
  • Male or female adults ages 50 years or older on the day of screening who have cataracts in both eyes
  • Regular corneal astigmatism (measured by topographer)
  • Astigmatism ≤1.0 D (measured by an automatic keratometer)
  • Clear intraocular media other than cataract
  • Availability, willingness and sufficient cognitive awareness to comply with examination procedures
  • Patient is willing to receive bilateral implantation of a trifocal IOL (this inclusion criteria applies only to the study group, not the control group)
  • Signed informed consent

Who cannot take part

  • Previous intraocular or corneal surgery
  • Expected complicated surgery
  • Concurrent participation in another drug or device investigation; In addition to above mentioned in- and exclusion criteria, subjects shall be discontinued when certain conditions are present at the time of surgery, including:
  • Difficulty for cooperation (distance from their home, general health conditions)
  • Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal or optic disorders)
  • Ocular hypertension, suspicious glaucoma or glaucoma
  • Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils or pupils that do not dilate under mesopic / scotopic conditions)
  • Ocular surface disease (clinical symptoms or keratitis)
  • inability to fixate IOL in desired position. In such cases, the subject shall be followed until the condition has stabilized
  • Age of patient < 50 years
  • Regular corneal astigmatism >1.0 dioptres (measured by an automatic keratometer)
  • Irregular astigmatism (measured by topographer)
  • Subjects with AMD suspicious eyes as determined by OCT examination
  • Traumatic cataract
  • Instability of keratometry or biometry measurements; Acceptable maximum standard deviation: AL: ± 150 µm; ACD: ± 150 µm; K1 / K2: ± 0.15 D
  • Pregnancy or lactation
  • Second eye treatment will only be performed when Best Corrected Distance Visual Acuity (CDVA) of first eye is ≤ 0.2 logMAR (≥ 0.63 decimal)
  • zonular instability
  • need for iris manipulation
  • capsular fibrosis or other opacity; and

Where is this trial?

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study will be a multicentric, prospective open-label ethics committee approved clinical study to investigate safety, visual outcomes, contrast sensitivity and rotational stability after bilateral implantation of Isatis TF IOL following cataract surgery.

The 2 groups in the trial

  • IOL implantation experimentalTreatment being tested

    Experimental arm: Trifocal intraocular lens Isatis TF

    Treatment: Implantation of trifocal IOL, Isatis TF (device under investigation)

  • IOL implantation active comparatorExisting treatment, for comparison

    Comparator arm: Monofocal intraocular lens Isatis

    Treatment: Implantation of monofocal IOL, Isatis (control device)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Multicentric Clinical Study to Determine Safety and Efficacy of a Hydrophobic Acrylic Trifocal Intraocular Lens (IOL)
Record updated
12 February 2025